JEJenny Epstein

Jenny Epstein

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jenny Epstein has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • IBD 8 Perceptions of Young People with Inflammatory Bowel Disease and their Parents/Carers regarding a Digital Personal Health Record

    by Intan Yeop, Philippa Howsley, Richard Hansen, Margaret Lee, Jenny Epstein, Priya Narula

    Objectives Digital personal health records (DPHR) have great potential to empower and equip young people (YP) to effectively manage their health condition. This study aimed to understand the views, requirements and concerns of YP with Inflammatory Bowel Disease (IBD) and their parents/carers regarding a developmentally appropriate and user-friendly DPHR. Design Sheffield Children’s NHS Foundation Trust, NIHR Children and Young People MedTech Co-operative and Crohn’s in Childhood Research Association (CICRA) collaborated to develop and circulate YP and parent/carer versions of the survey to all YP and parents registered with CICRA. Survey respondents were given the options of ‘yes, no or maybe’ in answer to the questions, with the opportunity of commenting on each question in the free text sections. Questions included were ‘Do you think it would be helpful if the app had alerts to remind you about your hospital appointments?’ and ‘What is your opinion of the app? 0=dislike, 100=like’. Responses were collected between January and February 2021. Results 25 YP (9–25 years (median 14); 64% female) and 93 parents/carers (44% female) across the UK completed the survey. Both YP and parents/carers rated the idea of the DPHR highly (YP: n=25, median 90(51–100)%; parents: n=86, median 100(4–100)%). YP and parents/carers would like easy access to information on IBD (YP:80%, parents/carers:89%) for themselves and to share with friends, family and teachers. Information about the transition process (YP:88%, parents/carers:97%), and information and contact details for the paediatric (YP:88%, parents/carers:95%) and adult (YP:88%, parents/carers:97%) clinical teams were felt to be helpful in supporting YP during this important period. The majority of YP and parents/carers would like access to their personal clinical records (YP:96%, parents/carers:89%), medication lists (YP:96%, parents/carers:95%), clinical laboratory results (YP: 84%, parents/carers:89%), endoscopy reports (YP:84%, parents/carers:84%), radiology reports (YP:76%, parents/carers: 84%) and hospital appointments (YP:96%, parents/carers:99%). They would also like information on emotional wellbeing (YP:80%; parents:92%), nutrition and diet (YP:60%; parents:87%), preparation for endoscopic procedures (YP:76%; parents:80%), medications and treatments (YP:84%; parents:86%), travel information (YP:84%; parents:93%) and research opportunities (YP:52%; parents:66%). YP and parents/carers would like interactive features such as symptom tracking function and disease activity indices (YP:84%; parents:88%). Most of the participants would also like the app to provide alerts and notifications for hospital appointments (YP:80%; parents:90%) and blood monitoring appointments (YP:80%; parents:82%). From the general comments made on a proposed DHPR, YP and parents/carers viewed knowledge on IBD positively and felt that it would be a useful tool to encourage YP involvement in their own care. Some parents/carers would like the ability to regulate the information accessed by their child to ensure that the information and functions are age-appropriate. Conclusion A DPHR would be welcomed by the majority of YP with IBD and their parents/carers. Further co-design with YP, parents/carers, and clinical teams is needed to understand the exact requirements of the app and its design, and to explore potential concerns.

  • Open Access

    Multiomic features associated with mucosal healing and inflammation in paediatric Crohn’s disease

    by Henry Taylor, Jose Ivan Serrano‐Contreras, Julie A. K. McDonald, Jenny Epstein, Jm Fell, Rocio C. Seoane, Jia V. Li, Julian R. Marchesi, Ailsa L. Hart

    Summary: Background: The gastrointestinal microbiota has an important role in mucosal immune homoeostasis and may contribute to maintaining mucosal healing in Crohn's disease (CD).Aim: To identify changes in the microbiota, metabolome and protease activity associated with mucosal healing in established paediatric CDMethods: Twenty‐five participants aged 3‐18 years with CD, disease duration of over 6 months, and maintenance treatment with biological therapy were recruited. They were divided into a low calprotectin group (faecal calprotectin 100 μg/g, “mucosal inflammation,” n = 11). 16S gene‐based metataxonomics, 1H‐NMR spectroscopy‐based metabolic profiling and protease activity assays were performed on stool samples.Results: Relative abundance of Dialister species was six‐times greater in the low calprotectin group (q = 0.00999). Alpha and beta diversity, total protease activity and inferred metagenomic profiles did not differ between groups. Pentanoate (valerate) and lysine were principal discriminators in a machine‐learning model which differentiated high and low calprotectin samples using NMR spectra (R2 0.87, Q2 0.41). Mean relative concentration of pentanoate was 1.35‐times greater in the low calprotectin group (95% CI 1.03‐1.68, P = 0.036) and was positively correlated with Dialister. Mean relative concentration of lysine was 1.54‐times greater in the high calprotectin group (95% CI 1.05‐2.03, P = 0.028).Conclusions: This multiomic study identified an increase in Dialister species and pentanoate, and a decrease in lysine, in patients with “mucosal healing.” It supports further investigation of these as potential novel therapeutic targets in CD.


  • Open Access

    Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel

    by Richard Hansen, Susanna Meade, R Mark Beattie, Marcus Kh Auth, Nick Croft, Philip Davies, David Devadason, Conor Docherty, Jenny Epstein, Lucy Howarth, et al.

    Objective Paediatric acute severe colitis (ASC) management during the novel SARS-CoV-2/COVID-19 pandemic is challenging due to reliance on immunosuppression and the potential for surgery. We aimed to provide COVID-19-specific guidance using the European Crohn’s and Colitis Organisation/European Society for Paediatric Gastroenterology, Hepatology and Nutrition guidelines for comparison. Design We convened a RAND appropriateness panel comprising 14 paediatric gastroenterologists and paediatric experts in surgery, rheumatology, respiratory and infectious diseases. Panellists rated the appropriateness of interventions for ASC in the context of the COVID-19 pandemic. Results were discussed at a moderated meeting prior to a second survey. Results Panellists recommended patients with ASC have a SARS-CoV-2 swab and expedited biological screening on admission and should be isolated. A positive swab should trigger discussion with a COVID-19 specialist. Sigmoidoscopy was recommended prior to escalation to second-line therapy or colectomy. Methylprednisolone was considered appropriate first-line management in all, including those with symptomatic COVID-19. Thromboprophylaxis was also recommended in all. In patients requiring second-line therapy, infliximab was considered appropriate irrespective of SARS-CoV-2 status. Delaying colectomy due to SARS-CoV-2 infection was considered inappropriate. Corticosteroid tapering over 8–10 weeks was deemed appropriate for all. After successful corticosteroid rescue, thiopurine maintenance was rated appropriate in patients with negative SARS-CoV-2 swab and asymptomatic patients with positive swab but uncertain in symptomatic COVID-19. Conclusion Our COVID-19-specific adaptations to paediatric ASC guidelines using a RAND panel generally support existing recommendations, particularly the use of corticosteroids and escalation to infliximab, irrespective of SARS-CoV-2 status. Consideration of routine prophylactic anticoagulation was recommended.


  • Open Access

    Safety and efficacy of parenteral iron in children with inflammatory bowel disease

    by Michael Papadopoulos, Deepa Patel, Roxanna Korologou‐Linden, Eunice Goto, Krishna Soondrum, John M. E. Fell, Jenny Epstein

    Aims: Iron deficiency anaemia frequently complicates inflammatory bowel disease (IBD) in children and adults. Oral iron may exacerbate gastrointestinal symptoms and absorption may be insufficient in intestinal inflammation. Even where oral iron is successful, repletion of iron stores can be unacceptably slow. Intravenous iron compounds were in the past associated with serious adverse reactions and historically were considered a last resort in children. New generation preparations have a safer profile in adults, although reluctance to use them in children may persist, where safety data are lacking. We investigate the safety and efficacy of ferric carboxymaltose and iron sucrose in children.Methods: We retrospectively identified all children with IBD who received parenteral iron over a 38‐month period in a single regional referral centre. Safety, tolerability and adverse events were established by case note review. Efficacy was assessed by change in haematinic indices pre‐ and post‐treatment.Results: Forty‐one children (18 male; median age 14 years, range 3–17) received a total of 104 iron infusions. Of these, 44% (18) had Crohn's disease; 56% (23) ulcerative colitis. Thirty‐five received ferric carboxymaltose, seven iron sucrose and one both. Three children developed mild rash post infusion which resolved quickly with chlorphenamine. Mean increase in haemoglobin was 2.5 g dl–1 (0.3–5.8). Iron levels increased by a mean of 8.4 g dl–1 (1–25), transferrin saturation by 16.2% (2–47). Transferrin decreased by 0.84 g dl–1 (0.3–3.4).Conclusions: New generation parenteral iron preparations are safe, well tolerated and efficacious in children with iron deficiency anaemia and IBD.


  • Open Access

    Local chemokine profiling in eosinophilic esophagitis: The synthetic absorptive matrix test

    by Eleanor Minshall, Harsita Patel, Nicholas Francis, Trevor T. Hansel, John O. Warner, Robert J. Boyle, John Fell, Jenny Epstein

  • Recent advances in the pathophysiology and management of eosinophilic oesophagitis

    by J. Epstein, J. O. Warner

    Summary: Eosinophilic oesophagitis is an increasingly recognized allergic gastrointestinal disease, which is becoming more common. Although the average age at diagnosis is 30–50 years, it often affects very young children and carries significant long‐term morbidity. While our understanding of its pathophysiology is accumulating, the precise pathways by which the disease arises remain unclear. There are inconsistencies in its diagnosis and definition, and a drive towards international standardization is underway. Current methods for diagnosis and monitoring are relatively invasive, and controversies surround their interpretation. Management strategies are imperfect and involve burdensome long‐term dietary exclusions, or drug treatments with uncertain efficacy or serious side‐effects. It is the focus of a rapidly increasing body of research, the latest insights from which are systematically presented in this review.